The development and use of novel iridium complexes as catalysts for ortho-directed hydrogen isotope exchange reactions

G.N. Nilsson, W.J. Kerr

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The preparation and application of groups of new iridium complexes are described. In particular, iridium complexes possessing phosphine ligands and a bulky N-heterocyclic carbene have been shown to be robust and readily handled species and have been applied in a range of directed hydrogen-deuterium and -tritium exchange processes and, in particular, with drug-like substrates or within ADMET-related studies. Overall, these new iridium(I) complexes are shown to be highly active catalysts and display catalytic activity far in excess of the industry standard, Crabtree's catalyst, with excellent levels of labelling being achieved over short reaction times and at low metal complex loadings, whilst tolerating a wide range of functional moieties. Furthermore and again in contrast to systems employing Crabtree's catalyst, the low catalyst loadings and short reaction times made possible by these emerging iridium carbene comple have delivered tritiated products with very good levels of labelling and without any appreciable by-product waste production.
LanguageEnglish
Pages662-667
Number of pages6
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Volume53
Issue number11-12
DOIs
Publication statusPublished - 15 Sep 2010

Fingerprint

Iridium
Isotopes
Hydrogen
Catalysts
phosphine
Labeling
Waste Products
Tritium
Deuterium
Coordination Complexes
Byproducts
Catalyst activity
Industry
Ligands
Substrates
Pharmaceutical Preparations
carbene

Keywords

  • iridium
  • compounds
  • pharmaceuticals
  • applied chemistry

Cite this

@article{b088cbd10e37480d86181878dc09edb4,
title = "The development and use of novel iridium complexes as catalysts for ortho-directed hydrogen isotope exchange reactions",
abstract = "The preparation and application of groups of new iridium complexes are described. In particular, iridium complexes possessing phosphine ligands and a bulky N-heterocyclic carbene have been shown to be robust and readily handled species and have been applied in a range of directed hydrogen-deuterium and -tritium exchange processes and, in particular, with drug-like substrates or within ADMET-related studies. Overall, these new iridium(I) complexes are shown to be highly active catalysts and display catalytic activity far in excess of the industry standard, Crabtree's catalyst, with excellent levels of labelling being achieved over short reaction times and at low metal complex loadings, whilst tolerating a wide range of functional moieties. Furthermore and again in contrast to systems employing Crabtree's catalyst, the low catalyst loadings and short reaction times made possible by these emerging iridium carbene comple have delivered tritiated products with very good levels of labelling and without any appreciable by-product waste production.",
keywords = "iridium, compounds, pharmaceuticals, applied chemistry",
author = "G.N. Nilsson and W.J. Kerr",
year = "2010",
month = "9",
day = "15",
doi = "10.1002/jlcr.1817",
language = "English",
volume = "53",
pages = "662--667",
journal = "Journal of Labelled Compounds and Radiopharmaceuticals",
issn = "0362-4803",
number = "11-12",

}

TY - JOUR

T1 - The development and use of novel iridium complexes as catalysts for ortho-directed hydrogen isotope exchange reactions

AU - Nilsson, G.N.

AU - Kerr, W.J.

PY - 2010/9/15

Y1 - 2010/9/15

N2 - The preparation and application of groups of new iridium complexes are described. In particular, iridium complexes possessing phosphine ligands and a bulky N-heterocyclic carbene have been shown to be robust and readily handled species and have been applied in a range of directed hydrogen-deuterium and -tritium exchange processes and, in particular, with drug-like substrates or within ADMET-related studies. Overall, these new iridium(I) complexes are shown to be highly active catalysts and display catalytic activity far in excess of the industry standard, Crabtree's catalyst, with excellent levels of labelling being achieved over short reaction times and at low metal complex loadings, whilst tolerating a wide range of functional moieties. Furthermore and again in contrast to systems employing Crabtree's catalyst, the low catalyst loadings and short reaction times made possible by these emerging iridium carbene comple have delivered tritiated products with very good levels of labelling and without any appreciable by-product waste production.

AB - The preparation and application of groups of new iridium complexes are described. In particular, iridium complexes possessing phosphine ligands and a bulky N-heterocyclic carbene have been shown to be robust and readily handled species and have been applied in a range of directed hydrogen-deuterium and -tritium exchange processes and, in particular, with drug-like substrates or within ADMET-related studies. Overall, these new iridium(I) complexes are shown to be highly active catalysts and display catalytic activity far in excess of the industry standard, Crabtree's catalyst, with excellent levels of labelling being achieved over short reaction times and at low metal complex loadings, whilst tolerating a wide range of functional moieties. Furthermore and again in contrast to systems employing Crabtree's catalyst, the low catalyst loadings and short reaction times made possible by these emerging iridium carbene comple have delivered tritiated products with very good levels of labelling and without any appreciable by-product waste production.

KW - iridium

KW - compounds

KW - pharmaceuticals

KW - applied chemistry

U2 - 10.1002/jlcr.1817

DO - 10.1002/jlcr.1817

M3 - Article

VL - 53

SP - 662

EP - 667

JO - Journal of Labelled Compounds and Radiopharmaceuticals

T2 - Journal of Labelled Compounds and Radiopharmaceuticals

JF - Journal of Labelled Compounds and Radiopharmaceuticals

SN - 0362-4803

IS - 11-12

ER -